Endogenous opioids mediate basal hedonic tone independent of dopamine d-1 or d-2 receptor activation

Neuroscience

Volumn 124, Issue 1, 2004, Pages 241-246

  Narayanan, S ^a,d   Lam, H ^a   Christian, L ^a   Levine, M S ^a   Grandy, D ^b   Rubinstein, M ^c   Maidment, N T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d Glenmark Pharmaceuticals Limited   (India)

Author keywords

Aversion; Dopamine receptor; Drug abuse; Opioid; Place conditioning; Reward

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; ENDORPHIN; NALOXONE;

ANIMAL EXPERIMENT; ARTICLE; AVERSION; DOPAMINERGIC SYSTEM; DRUG EFFECT; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; REWARD;

EID: 0442276483     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2003.11.011     Document Type: Article

References (57)

1. Acquas E., Carboni E., Leone P., Di Chiara G. SCH 23390 blocks drug-conditioned place-preference and place-aversion anhedonia (lack of reward) or apathy (lack of motivation) after dopamine-receptor blockade? Psychopharmacol. 99:1989;151-155.
2. Acquas E., Di Chiara G. D1 receptor blockade stereospecifically impairs the acquisition of drug-conditioned place preference and place aversion. Behav Pharmacol. 5:1994;555-569.
3. Ahmed S.H., Koob G.H. Transition from moderate to excessive drug intake change in hedonic set point . Science. 282:1998;298-300.
4. Bals-Kubik R., Ableitner A., Herz A., Shippenberg T.S. Neuroanatomical sites mediating the motivational effects of opioids mapped by the conditioned place paradigm in rats. J Pharmacol Exp Ther. 264:1993;489-495.
5. Bals-Kubik R., Herz A., Shippenberg T.S. Evidence that the aversive effects of opioid antagonists and kappa-agonists are centrally mediated. Psychopharmacology. 98:1989;203-206.
6. Bozarth M.A. Neuroanatomical boundaries of the reward-relevant opiate-receptor field in the ventral tegmental area as mapped by the conditioned place preference method in rats. Brain Res. 414:1987;77-84.
7. Bozarth M.A., Wise R.A. Heroin reward is dependent on a dopaminergic substrate. Life Sci. 29:1981;1881-1886.
8. Bozarth M.A., Wise R.A. Neural substrates of opiate reinforcement. Prog Neuropsychopharmacol Biol Psychiatry. 7:1983;569-575.
9. Di Chiara G. A motivational learning hypothesis of the role of mesolimbic dopamine in compulsive drug use. J Psychopharmacol. 12:1998;54-67.
10. Di Chiara G., North R.A. Neurobiology of opiate abuse. Trends Pharmacol Sci. 13:1992;185-193.
11. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA. 85:1988;5274-5278.
12. Dockstader C.L., Rubinstein M., Grandy D.K., Low M.J., van der Kooy D. The d2 receptor is critical in mediating opiate motivation only in opiate-dependent and withdrawn mice. Eur J Neurosci. 13:2001;995-1001.
13. Drago J., Gerfen C.R., Lachowicz J.E., Steiner H., Hollon T.R., Love P.E., Ooi G.T., Grinberg A., Lee E.J., Huang S.P., Bartlett P.F., Jose P.A., Sible D.R., Westphal H. Altered function in a mutant mouse lacking D1A dopamine receptors. Proc Natl Acad Sci USA. 91:1994;12564-12568.
14. Dworkin S.I., Guerin G.F., Co C., Goeders N.E., Smith J.E. Lack of an effect of 6-hydroxydopamine lesions of the nucleus accumbens on intravenous morphine self-administration. Pharmacol Biochem Behav. 30:1988;1051-1057.
15. Dworkin S.I., Guerin G.F., Goeders N.E., Smith J.E. Kainic acid lesions of the nucleus accumbens selectively attenuate morphine self-administration. Pharmacol Biochem Behav. 29:1988;175-181.
16. Elmer G.I., Pieper J.O., Rubinstein M., Low M.J., Grandy D.K., Wise R.A. Failure of intravenous morphine to serve as an effective instrumental reinforcer in dopamine D2 receptor knock-out mice. J Neurosci. 22:2002;RC224.
17. Ettenberg A. Dopamine, neuroleptics and reinforced behavior. Neurosci Biobehav Rev. 13:1989;105-111.
18. Everitt B.J., Dickinson A., Robbins T.W. The neuropsychological basis of addictive behavior. Brain Res Rev. 36:2001;129-138.
19. Grevert P., Goldstein A. Effects of naloxone on experimentally induced ischemic pain and on mood in human subjects. Proc Natl Acad Sci USA. 74:1977;1291-1294.
20. Grevert P., Goldstein A. Some effects of naloxone on behavior in the mouse. Psychopharmacology. 53:1977;111-113.
21. Hollister L.E., Johnson K., Boukhabza D., Gillespie H.K. Aversive effects of naltrexone in subjects not dependent on opiates. Drug Alcohol Depend. 8:1981;37-41.
22. Hubner C.B., Koob G.F. The ventral pallidum plays a role in mediating cocaine and heroin self-administration in the rat. Brain Res. 508:1990;20-29.
23. Johnson S.W., North R.A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci. 12:1992;483-488.
24. Kelley A.E., Berridge K.C. The neuroscience of natural rewards relevance to addictive drugs . J Neurosci. 22:2002;3306-3311.
25. Kelly M.A., Rubinstein M., Asa S., Zhang G., Saez C., Bunzow J.R., Allen R., Hnasko R., Ben-Jonathon N., Grandy D.K., Low M.J. Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron. 19:1997;103-113.
26. Kelly M.A., Rubinstein M., Phillips T.J., Lessov C.N., Burkhart-Kasch S., Zhang G., Bunzow J.R., Fang Y., Gerhardt G.A., Grandy D.K., Low M.J. Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J Neurosci. 18:1998;3470-3479.
27. Koob G.F. Drugs of abuse anatomy, pharmacology and function of reward pathways . Trends Pharmacol Sci. 13:1992;177-184.
28. Koob G.F., Le Moal M. Drug abuse hedonic homeostatic dysregulation . Science. 278:1997;52-58.
29. Koob G.F., Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology. 24:2001;97-129.
30. Leone P., Di Chiara G. Blockade of D-1 receptors by SCH 23390 antagonizes morphine- and amphetamine-induced place preference conditioning. Eur J Pharmacol. 135:1987;251-254.
31. Leone P., Pocock D., Wise R.A. Morphine-dopamine interaction ventral tegmental morphine increases nucleus accumbens dopamine release . Pharmacol Biochem Behav. 39:1991;469-472.
32. Mackey W.B., van der Kooy D. Neuroleptics block the positive reinforcing effects of amphetamine but not of morphine as measured by place preference conditioning. Pharmacol Biochem Behav. 22:1985;101-105.
33. Maldonado R., Saiardi A., Valverde O., Samad T.A., Roques B.P., Borrelli E. Absence of opiate rewarding effects in mice lacking D2 receptors. Nature. 388:1997;586-589.
34. Millan M.J., Newman-Tancredi A., Quentric Y., Cussac D. The "selective" dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin2C receptors. Psychopharmacology. 156:2001;58-62.
35. Mucha R.F., Iversen S.D. Reinforcing properties of morphine and naloxone revealed by conditioned place preferences a procedural examination . Psychopharmacology. 82:1984;241-247.
36. Mucha R.F., Millan M.J., Herz A. Aversive properties of naloxone in non-dependent (naive) rats may involve blockade of central beta-endorphin. Psychopharmacology. 86:1985;281-285.
37. Mucha R.F., van der Kooy D., O'Shaughnessy M., Bucenieks P. Drug reinforcement studied by the use of place conditioning in rat. Brain Res. 243:1982;91-105.
38. Mucha R.F., Walker M.J. Aversive property of opioid receptor blockade in drug-naive mice. Psychopharmacology. 93:1987;483-488.
39. Murphy N.P., Lam H.A., Maidment N.T. A comparison of morphine-induced mesolimbic dopamine release and locomotor activity in C57BL6, Sv129 and DBA2 mice. J Neurochem. 79:2001;626-635.
40. Pettit H.O., Ettenberg A., Bloom F.E., Koob G.F. Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats. Psychopharmacology. 84:1984;167-173.
41. Phillips A.G., LePiane F.G. Reinforcing effects of morphine microinjection into the ventral tegmental area. Pharmacol Biochem Behav. 12:1980;965-968.
42. Phillips A.G., LePiane F.G. Reward produced by microinjection of (D-Ala2), Met5-enkephalinamide into the ventral tegmental area. Behav Brain Res. 5:1982;225-229.
43. Robinson T.E., Berridge K.C. The neural basis of drug craving an incentive sensitization theory of addiction . Brain Res Rev. 18:1993;247-291.
44. Robinson T.E., Berridge K.C. The psychology and neurobiology of addiction an incentive-sensitization view . Addiction. 95:(Suppl 2):2000;S91-117.
45. Schwartz A.S., Marchok P.L. Depression of morphine-seeking behaviour by dopamine inhibition. Nature. 248:1974;257-258.
46. Shippenberg T.S., Bals-Kubik R. Involvement of the mesolimbic dopamine system in mediating the aversive effects of opioid antagonists in the rat. Behav Pharmacol. 6:1995;99-106.
47. Shippenberg T.S., Bals-Kubik R., Herz A. Examination of the neurochemical substrates mediating the motivational effects of opioids role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors . J Pharmacol Exp Ther. 265:1993;53-59.
48. Shippenberg T.S., Herz A. Motivational effects of opioids influence of D-1 versus D-2 receptor antagonists . Eur J Pharmacol. 151:1988;233-242.
49. Skoubis P.D., Matthes H.W., Walwyn W.M., Kieffer B.L., Maidment N.T. Naloxone fails to produce conditioned place aversion in mu-opioid receptor knockout mice. Neuroscience. 106:2001;757-763.
50. Skoubis P.D., Maidment N.T. Blockade of ventral pallidal opioid receptors induces a conditioned place aversion and blocks acquisition of cocaine place preference in the rat. Neuroscience. 119:2003;241-249.
51. Spanagel R., Herz A., Shippenberg T.S. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA. 89:1992;2046-2050.
52. Spyraki C., Fibiger H.C., Phillips A.G. Attenuation of heroin reward in rats by disruption of the mesolimbic dopamine system. Psychopharmacology. 79:1983;278-283.
53. van Ree J.M., Gerits M.A., Vanderschuren L.J. Opioids, reward and addiction an encounter of biology, psychology and medicine . Pharmacol Rev. 51:1999;341-396.
54. Wise R.A., Bozarth M.A. A psychomotor stimulant theory of addiction. Psychol Rev. 94:1987;469-492.
55. Wise R.A., Bozarth M.A. Actions of drugs of abuse on brain reward systems an update with specific attention to opiates . Pharmacol Biochem Behav. 17:1982;239-243.
56. Zahm D.S., Zaborszky L., Alones V.E., Heimer L. Evidence for the coexistence of glutamate decarboxylase and Met-enkephalin immunoreactivities in axon terminals of rat ventral pallidum. Brain Res. 325:1985;317-321.
57. Zito K.A., Vickers G., Roberts D.C. Disruption of cocaine and heroin self-administration following kainic acid lesions of the nucleus accumbens. Pharmacol Biochem Behav. 23:1985;1029-1036.